NCT07384728

Brief Summary

This study aims to examine the effects of fasting during Ramadan on treatment adherence, psychological adjustment, and glycemic control in individuals with type 2 diabetes. While Ramadan fasting is a religious practice, it can also pose health risks such as hypoglycemia, hyperglycemia, and metabolic imbalance in individuals with diabetes. Adherence to treatment and self-care, as well as psychosocial adjustment, are crucial in the effective management of diabetes. Given that a large portion of Turkey's population is Muslim, comparing individuals with type 2 diabetes who fast and those who do not during Ramadan will contribute to improving patient care within a cultural and religious context. The findings of this study are expected to guide nurses in developing personalized, culturally sensitive care plans tailored to the needs of individuals before, during, and after Ramadan.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for not_applicable type-2-diabetes

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable type-2-diabetes

Geographic Reach
1 country

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2026

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

January 6, 2026

Completed
28 days until next milestone

First Posted

Study publicly available on registry

February 3, 2026

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2026

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 20, 2026

Completed
Last Updated

February 3, 2026

Status Verified

January 1, 2026

Enrollment Period

2 months

First QC Date

January 6, 2026

Last Update Submit

January 26, 2026

Conditions

Keywords

Type 2 diabetesRamadan experienceTreatmentPsychologicalGlycemic control

Outcome Measures

Primary Outcomes (4)

  • 1. Parametre

    HbA1c 2-4 weeks before Ramadan (basic assessment).

    2-4 weeks

  • 2. Parametre

    Treatment Adherence Scale, 2-4 weeks before Ramadan This scale was developed to evaluate "Patient Adherence in Type 2 Diabetes Mellitus Treatment." Validity and reliability analyses have shown it to be a valid and reliable scale. Based on the scores obtained from the scale, adherence is considered good if patients are doing what they should and not doing what they shouldn't, despite factors affecting treatment adherence. The scale: * Is administered to patients with type 2 diabetes for at least one year. • Consists of 30 items in total. * A 5-point Likert scale is used for scoring. • Patients indicate the most appropriate option for each statement on the scale using a 5-point Likert scale (Strongly agree=1, Agree=2, Partially agree=3, Disagree=4, and Strongly disagree=5). • The scale contains 13 items representing positive attitudes and 17 items representing negative attitudes. In scoring, positive items (1, 3, 5, 8, 13, 15, 16, 17, 19, 23, 25, 26, 29) are scor

    2-4 weeks

  • 3. Parametre

    Psychological and Adherence Impact Scale 2-4 weeks before Ramadan. The BASE-6 was developed by Cruz et al. (2019) and it is a self-report instrument of general psychological adjustment comprising of six items. Each item assesses how a participant has been feeling in the past week. Items are rated on a 7-point scale (ranging from 1 = Not at all to 5 = Extremely). A sample item is "To what extent have you felt irritable, angry, and/or resentful this week?". Using three different adult samples, the original study demonstrated good internal consistency (α = .87-.93) and test-retest reliability (intraclass correlation was .77) over one-week period.

    2-4 weeks

  • Post-Ramadan 2. Parametre

    Treatment adherence will be assessed using the Treatment Adherence Scale for Type 2 Diabetes Mellitus, a validated and reliable 30-item, 5-point Likert scale. Patients rate each item from strongly agree to strongly disagree. Higher scores indicate better adherence to diabetes treatment.

    Post-Ramadan: 1-2 months after

Secondary Outcomes (2)

  • Post-Ramadan 1. Parametre

    Post-Ramadan: 1-2 months after

  • Post-Ramadan 3. Parametre

    Post-Ramadan: 1-2 months after

Study Arms (2)

Experimental group: Individuals observing the fast.

EXPERIMENTAL

Patients in the experimental group received face-to-face dietary education from the researcher in the waiting room for approximately 15 minutes, and were given an "Information Brochure." Pre-education (pre-test) data collection tools were administered to diabetic patients. All data collection tools were administered to these patients, except for the structured Patient Information Form, which was completed one month after Ramadan 2026.

Other: The effect of fasting and not fasting during Ramadan.

No Intervention: Control Group

NO INTERVENTION

Diabetic patients in this group were classified as a non-fasting group. No intervention was applied. Only data collection forms were administered before the study (pre-test) and after Ramadan 2026.

Interventions

The effects of fasting and non-fasting during Ramadan on treatment adherence, psychological adjustment, and glycemic control.

Also known as: The effect of fasting during Ramadan
Experimental group: Individuals observing the fast.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals ≥18 years of age
  • Able to give informed consent
  • Diagnosed with type 2 diabetes
  • Planning to fast during Ramadan

You may not qualify if:

  • Presence of psychiatric illness
  • Presence of cognitive impairment
  • Receiving additional treatments that significantly affect glucose levels (e.g., ongoing steroid therapy)
  • Individuals who have decided not to fast during Ramadan
  • Individuals who have stopped fasting during Ramadan

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Gümüşhane Universıty

Gümüşhane, Kelkit, 2900, Turkey (Türkiye)

Location

Gümüşhane Üniversitesi

Gümüşhane, Kelkit, 29100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Dilan aktepe coşar, PhD

    Gümüşhane Universıty

    STUDY DIRECTOR

Central Study Contacts

Dilan aktepe coşar, PhD

CONTACT

Hatice Demirağ, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
Patients were randomly assigned to groups, and interviews were scheduled at different times to minimize the possibility of interaction between them. Additionally, patients were informed about the study and their consent was obtained prior to the study.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: This research is a clinical trial designed to examine the effects of fasting during Ramadan on treatment adherence, psychological adjustment, and glycemic control in individuals with type 2 diabetes. The study compares individuals who fast and those who do not fast during Ramadan to evaluate the relevant variables. Participants are monitored before and after Ramadan; glycemic control, treatment adherence, and psychological adjustment are measured using standardized measurement tools. The study model aims to guide clinical practice and nursing care with the results obtained.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
lecture

Study Record Dates

First Submitted

January 6, 2026

First Posted

February 3, 2026

Study Start

January 3, 2026

Primary Completion

February 20, 2026

Study Completion

March 20, 2026

Last Updated

February 3, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Individual patient data will not be shared due to the need to protect participant confidentiality, the privacy of personal health information, and compliance with applicable ethical committee approval and data protection legislation (KVKK). Data will only be analyzed for scientific purposes in an anonymized and aggregated form, and there are no plans to share raw data containing individually identifying information with third parties. This approach has been adopted to protect participant rights and ensure compliance with ethical research principles.

Locations